China smartphone shipments slumped in June on inventory overhang: Jefferies
Arteris , Inc. (NASDAQ:AIP), a $323 million market cap company, recently reported a stock transaction by its President and CEO, Janac K Charles. According to the SEC Form 4 filing, Charles sold 1,973 shares of common stock on March 5, 2025, at a price of $8.19 per share. The sale comes amid a challenging period for the stock, which has declined about 13% in the past week. InvestingPro data shows analyst targets ranging from $11 to $16, suggesting potential upside from current levels. This transaction was executed under a 10b5-1 trading plan, resulting in a total sale value of $16,158.
Following this sale, Charles directly owns 325,267 shares. Additionally, he has indirect ownership through Bayview Legacy, LLC, with 9,907,691 shares, and through the Charles and Lydia Janac Trust, with 56,252 shares. The filing underscores Charles’s continued significant stake in the company, both directly and indirectly.
In other recent news, Arteris, Inc. has been the focus of attention with notable developments influencing its financial outlook. Northland analysts have raised their price target for Arteris shares to $16, maintaining an Outperform rating. This adjustment comes after Arteris reported revenue that met expectations and guidance that aligned with forecasts. The company’s recent product launch, FlexGen, is expected to boost its average selling price by 30%, and 13 customers are currently evaluating this new offering, indicating potential future revenue growth. Meanwhile, Jefferies analyst Blayne Curtis has increased Arteris’ price target to $11, retaining a Hold rating due to cautious optimism about the company’s progress in the microcontroller unit market and its FlexGen solution.
Arteris’ recent success includes a significant win in the microcontroller unit market, which is anticipated to positively impact its financial performance. The company reported bookings of approximately $33.6 million for the quarter, achieving a book-to-bill ratio of 2.2:1, with the FlexNoC 5 product accounting for a substantial portion of interconnect licenses. Despite the positive developments, Jefferies remains cautious, citing lower-than-expected 2025 guidance as a reason for maintaining the Hold rating. Both analyst firms highlight the strategic significance of Arteris’ recent product introductions and market moves, which suggest potential growth and a quicker path to profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.